You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

You’ve been redirected to the new Cancer Care Ontario website. You can also visit the archived website, which is no longer being maintained.

Liposomal Anthracyclines in the Management of HIV-positive Kaposi's Sarcoma

Version: 2 ID: 12-8 Jun 2013
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
N. Iscoe, V. Bramwell, M. Charette, T. Oliver, B. Zanke, Systemic Treatment Disease Site Group

Patient Population

Patients with HIV-positive Kaposi’s sarcoma and good performance status (Eastern Cooperative Oncology Group [ECOG] 0-2) who have progressive cutaneous disease despite prior treatment with interferon and/or vinblastine, or who have visceral disease that is symptomatic or progressive.

Research Question(s)

Does liposomal anthracycline therapy have advantages over standard combination therapy for patients with human immunodeficiency virus (HIV)-positive Kaposi’s sarcoma who have aggressive cutaneous or visceral disease?

Outcomes of interest are survival, time-totreatment failure, response rates, adverse effects, and quality of life.

pdf download Summary (PDF) (428.92 KB)
pdf download Full Report (PDF) (877.47 KB)